Pulmonary Embolism - Pathophysiology

SECTION 1

Historical Context & Motivation

The recognition of pulmonary embolism (PE) as a distinct and life-threatening clinical entity evolved over several centuries, driven by advances in anatomy, pathology, and diagnostic technology. Early physicians observed sudden death in postoperative and immobilized patients but lacked the conceptual framework to attribute these events to thromboembolic disease. The interplay between venous thrombosis and pulmonary arterial obstruction was only gradually elucidated as gross anatomical dissection gave way to microscopic and imaging-based investigations.

1856 • Virchow's Triad

Rudolf Virchow described the three pathogenic factors of venous thrombosis—stasis, endothelial injury, and hypercoagulability—and formally proposed that thrombi originating in the deep veins could embolize to the pulmonary arteries, establishing the modern concept of venous thromboembolism.

1922 • First Use of Heparin

Following the isolation of heparin by Jay McLean in 1916, researchers began applying anticoagulant therapy to thromboembolic disease. By the early 1920s, heparin was used experimentally in animals, paving the way for the pharmacologic prevention of PE.

1964 • Pulmonary Angiography

Selective pulmonary angiography became the gold standard for diagnosing PE, allowing direct visualization of thrombus within pulmonary arteries and prompting development of risk-stratification tools.

1990s • CT Pulmonary Angiography (CTPA)

The advent of helical CT scanning transformed PE diagnosis by providing rapid, non-invasive imaging with high sensitivity and specificity, eventually supplanting conventional angiography as the primary diagnostic modality.

2019 • Modern Risk Stratification

The European Society of Cardiology published updated guidelines integrating clinical scoring systems (PESI/sPESI), biomarkers (troponin, BNP), and imaging findings into a unified algorithm for risk-adapted management of acute PE.

Despite these advances, pulmonary embolism remains the third most common cause of cardiovascular death worldwide, with an estimated 100,000–180,000 deaths annually in the United States alone. The central question this lesson addresses is: How does obstruction of pulmonary vasculature by embolic material produce the cascade of hemodynamic collapse, gas exchange failure, and end-organ injury observed clinically?

SECTION 2

Core Principles & Definitions

Understanding pulmonary embolism requires integrating concepts from vascular biology, hemodynamics, and respiratory physiology. At its core, PE involves the migration of a thrombus—most commonly originating from the deep veins of the lower extremities—into the pulmonary arterial circulation, where it produces mechanical obstruction and triggers a series of neurohumoral and inflammatory responses. The severity of the resulting pathophysiology depends on the degree of vascular occlusion, the patient's cardiopulmonary reserve, and the host inflammatory response.

Virchow's Triad

The three predisposing conditions for venous thrombosis: venous stasis (reduced blood flow), endothelial injury (vessel wall damage), and hypercoagulability (prothrombotic state). These factors interact to promote thrombus formation in the venous system.

Dead Space Ventilation

When a pulmonary artery is occluded, the distal alveoli continue to be ventilated but no longer receive perfusion. This creates alveolar dead space—wasted ventilation that cannot participate in gas exchange, leading to ventilation-perfusion (V/Q) mismatch.

Right Ventricular Afterload

Mechanical obstruction of the pulmonary vascular bed raises pulmonary vascular resistance (PVR), acutely increasing right ventricular (RV) afterload. The thin-walled RV is poorly equipped to handle sudden pressure overload, leading to dilation and potential failure.

Neurohumoral Response

Platelet activation at the thrombus surface releases serotonin and thromboxane A₂, potent vasoconstrictors and bronchoconstrictors that amplify the hemodynamic and ventilatory consequences beyond the degree of mechanical obstruction alone.

✦

KEY TAKEAWAY

Think of pulmonary embolism like a dam built across one branch of a river delta. Downstream, the land (alveoli) receives no water (blood) and goes dry—creating dead space. Upstream, the water pressure (RV afterload) rises dramatically against the dam. Meanwhile, chemical signals released by the dam's construction cause neighboring channels to narrow, worsening the flood upstream even further. The combined effect of mechanical obstruction plus chemical vasoconstriction explains why a clot blocking 30% of the vasculature can produce hemodynamic effects disproportionate to its size.

SECTION 3

Pathophysiological Cascade — Visual Explanation

This flowchart traces the two parallel pathophysiological pathways of PE: the hemodynamic pathway (left, pink) involving rising pulmonary vascular resistance, RV failure, and reduced cardiac output, and the gas exchange pathway (right, amber) involving dead space ventilation, V/Q mismatch, and hypoxemia. Both converge to produce obstructive shock.

The diagram above illustrates how a single pathological event—thrombus lodging in the pulmonary arterial tree—initiates two parallel but interrelated cascades. On the hemodynamic side, the acute rise in pulmonary vascular resistance forces the right ventricle to generate higher pressures to maintain flow across the obstructed bed. Because the RV is a thin-walled, high-compliance chamber designed for a low-pressure system, it cannot sustain this increased afterload; it dilates, the interventricular septum bows leftward (impairing LV filling), and cardiac output falls. Simultaneously, on the gas exchange side, the creation of alveolar dead space increases the physiologic dead space fraction, wastes minute ventilation, and produces V/Q mismatch. Blood is shunted toward non-obstructed vascular beds, which become overperfused relative to their ventilation, further degrading gas exchange and driving arterial hypoxemia. Neurohumoral mediators released from activated platelets potentiate both pathways simultaneously.

SECTION 4

Hemodynamic & Gas Exchange Mechanisms

Hemodynamic Consequences

The hemodynamic impact of PE can be quantified through well-established physiological relationships. The pulmonary vascular resistance (PVR) is the critical variable linking vascular obstruction to right heart failure. Under normal conditions, the pulmonary circulation is a low-resistance, highly recruitable bed. When ≥30–50% of the cross-sectional area is obstructed, the compensatory reserve is exhausted and mean pulmonary artery pressure (mPAP) rises sharply. The non-conditioned right ventricle can acutely generate systolic pressures of only ~50–60 mmHg before decompensating.

PULMONARY VASCULAR RESISTANCE

PVR = (mPAP − PCWP) / CO × 80

Where mPAP = mean pulmonary artery pressure (mmHg), PCWP = pulmonary capillary wedge pressure (mmHg), CO = cardiac output (L/min). The factor of 80 converts Wood units to dyn·s·cm⁻⁵. Normal PVR is 100–250 dyn·s·cm⁻⁵.

Gas Exchange Consequences

The gas exchange derangement in PE is characterized by an increase in physiologic dead space and widening of the alveolar-arterial (A-a) oxygen gradient. The Bohr equation quantifies the dead space fraction, while the A-a gradient quantifies the efficiency of oxygen transfer from alveolus to arterial blood. In massive PE, the dead space fraction (V_D/V_T) can exceed 0.5, meaning more than half of each breath fails to participate in gas exchange.

ALVEOLAR-ARTERIAL GRADIENT

A-a gradient = [FiO₂ × (P_atm − P_H₂O) − (PaCO₂ / R)] − PaO₂

Where FiO₂ = fraction of inspired oxygen, P_atm = atmospheric pressure (760 mmHg at sea level), $P_H$ ₂O = water vapor pressure (47 mmHg), R = respiratory exchange ratio (≈ 0.8), PaO₂ = arterial partial pressure of oxygen. Normal A-a gradient ≈ 5–15 mmHg in young adults; in PE, it often exceeds 30–40 mmHg.

DEAD SPACE FRACTION (BOHR EQUATION)

V_D / V_T = (PaCO₂ − P_ECO₂) / PaCO₂

Where $V_D$ = dead space volume, $V_T$ = tidal volume, PaCO₂ = arterial CO₂, and P_ECO₂ = mixed expired CO₂. A rising $V_D$ / $V_T$ in the setting of acute dyspnea strongly suggests PE.

⚠

Clinical Correlation

A widened A-a gradient with a respiratory alkalosis (low PaCO₂ from tachypnea) is the classic arterial blood gas pattern in PE. However, approximately 20% of patients with confirmed PE may have a normal A-a gradient, so a normal value does not exclude the diagnosis.

SECTION 5

Classification & Risk Stratification

Pulmonary embolism spans a wide clinical spectrum, from small subsegmental clots that are incidentally discovered on imaging to massive saddle emboli causing immediate cardiovascular collapse. Modern classification frameworks categorize PE based on hemodynamic impact and right ventricular function rather than anatomical clot burden alone, reflecting the understanding that the host response (cardiac reserve, vasoactive mediator release) is as important as the degree of mechanical obstruction.

PE is stratified into low-risk, intermediate-risk (submassive), and high-risk (massive) categories based on hemodynamic stability, RV function, and biomarkers. The sPESI score helps differentiate low-risk from non-low-risk patients at the bedside.

The distinction between submassive and massive PE is clinically paramount because it determines the aggressiveness of intervention. Massive PE is defined by sustained systemic hypotension (systolic blood pressure <90 mmHg for ≥15 minutes, need for vasopressors, or cardiac arrest) and warrants emergent thrombolysis or surgical embolectomy. Submassive PE refers to hemodynamically stable patients who nonetheless demonstrate evidence of RV strain on imaging (RV/LV ratio >1.0 on CT) and/or elevated cardiac biomarkers (troponin, BNP/NT-proBNP). These patients represent a challenging "gray zone" where close monitoring and potential escalation to advanced therapies such as catheter-directed thrombolysis may be warranted.

SECTION 6

Clinical Case — Worked Example

A 62-year-old woman presents to the emergency department with acute-onset dyspnea and pleuritic chest pain 10 days after right total knee arthroplasty. Vital signs: HR 118 bpm, BP 108/72 mmHg, RR 28, SpO₂ 89% on room air. ABG on room air: pH 7.48, PaCO₂ 28 mmHg, PaO₂ 62 mmHg. CTPA confirms bilateral pulmonary emboli with RV/LV ratio of 1.3. Troponin I is elevated at 0.45 ng/mL. Let us work through the pathophysiological assessment.

Assessing Severity and Gas Exchange Impairment

1
Step 1 — Identify Risk Factors (Virchow's Triad)

This patient has multiple elements of Virchow's triad: recent surgery (endothelial injury), postoperative immobilization (venous stasis), and the prothrombotic state associated with surgical inflammation (hypercoagulability). These factors collectively predisposed her to deep venous thrombosis and subsequent embolization.

All three elements of Virchow's triad are present.
2
Step 2 — Calculate the A-a Gradient

Using FiO₂ = 0.21, P_atm = 760 mmHg, $P_H$ ₂O = 47 mmHg, PaCO₂ = 28 mmHg, R = 0.8, PaO₂ = 62 mmHg: PAO₂ = 0.21 × (760 − 47) − (28 / 0.8) = 0.21 × 713 − 35 = 149.7 − 35 = 114.7 mmHg. A-a gradient = 114.7 − 62 = 52.7 mmHg.

A-a gradient = 52.7 mmHg (markedly elevated; normal ≈ 5–15 mmHg)
3
Step 3 — Interpret ABG Pattern

The pH of 7.48 with a PaCO₂ of 28 mmHg indicates a primary respiratory alkalosis from tachypnea-driven hyperventilation. The low PaO₂ and widened A-a gradient confirm that the hypoxemia is due to a gas exchange defect (V/Q mismatch from dead space ventilation and intrapulmonary shunting) rather than pure hypoventilation.

Respiratory alkalosis + hypoxemia + widened A-a gradient = classic PE ABG pattern
4
Step 4 — Calculate sPESI Score

Evaluating sPESI criteria: Age >80? No (0). Cancer? No (0). Heart failure or chronic lung disease? No (0). HR ≥110? Yes (+1). SBP <100? No (0). SpO₂ <90? Yes (+1). Total sPESI = 2.

sPESI = 2 → Non-low-risk category
5
Step 5 — Classify PE Severity

The patient is hemodynamically stable (SBP >90 mmHg, no vasopressors), which excludes massive PE. However, she demonstrates RV dilation (RV/LV ratio 1.3 on CTPA) and elevated troponin (0.45 ng/mL), both markers of RV strain. This places her in the intermediate-high risk (submassive) category per ESC guidelines. Management includes systemic anticoagulation with unfractionated heparin, ICU monitoring, and consideration of escalation therapy (catheter-directed thrombolysis) if she deteriorates.

Diagnosis: Submassive (intermediate-high risk) PE requiring ICU monitoring and anticoagulation with potential escalation.

SECTION 7

Diagnostic Modalities — Strengths & Limitations

The diagnosis of PE relies on a stepwise approach that integrates clinical probability assessment with laboratory and imaging studies. Because the signs and symptoms of PE are nonspecific—dyspnea, tachycardia, chest pain, and hypoxemia occur in many cardiopulmonary conditions—clinicians must use validated decision tools to guide testing and avoid both missed diagnoses and unnecessary radiation exposure.

Diagnostic Modality	Strengths	Limitations
D-dimer	High sensitivity (~95%); excellent negative predictive value in low-risk patients; rapid, inexpensive bedside test	Low specificity; elevated in pregnancy, malignancy, infection, post-surgery, trauma; cannot confirm PE, only exclude it when negative in low-probability settings
CT Pulmonary Angiography (CTPA)	Gold standard for diagnosis; high sensitivity (95%) and specificity (97%); provides alternative diagnoses; assesses RV strain (RV/LV ratio)	Radiation exposure; IV contrast required (risk of nephrotoxicity and allergy); limited sensitivity for subsegmental emboli; reduced accuracy in motion artifact
V/Q Scintigraphy	No iodinated contrast; lower radiation than CTPA; useful in contrast allergy, renal insufficiency, and pregnancy	High proportion of 'indeterminate' results; limited availability; less useful in patients with underlying lung pathology (e.g., COPD) that alters baseline ventilation patterns
Echocardiography	Bedside availability; rapid assessment of RV function; can visualize thrombus in transit; essential for risk stratification	Cannot directly visualize thrombus in pulmonary arteries in most cases; operator-dependent; limited sensitivity for diagnosis (~50–60%)
Lower Extremity Duplex Ultrasound	Non-invasive; no radiation; finding of DVT in a patient with suspected PE can confirm venous thromboembolism diagnosis	Does not directly diagnose PE; negative result does not exclude PE (thrombus may have fully embolized); insensitive for pelvic DVT

Comparison of diagnostic modalities for pulmonary embolism

✦

KEY TAKEAWAY

The diagnostic approach to PE mirrors the engineering concept of a decision tree with sequential gates. The Wells score or Geneva score serves as the first gate—assigning clinical probability. If probability is low, the D-dimer acts as a highly sensitive filter: a negative result effectively closes the pipeline (PE excluded). If the D-dimer is positive or clinical probability is moderate-to-high, CTPA serves as the definitive confirmatory test. This sequential strategy optimizes the balance between diagnostic yield and resource utilization, much like a quality-control process that applies inexpensive screening before committing to expensive definitive testing.

SECTION 8

Treatment Approaches & Emerging Therapies

The management of PE has evolved from a one-size-fits-all anticoagulation approach to a risk-stratified framework in which the intensity of treatment is matched to the severity of the hemodynamic compromise. This section compares current standard therapies with emerging and advanced interventions, highlighting how pathophysiological understanding drives therapeutic decision-making.

Feature	Standard Anticoagulation	Systemic Thrombolysis	Catheter-Directed Therapy
Mechanism	Prevents clot propagation; relies on endogenous fibrinolysis to resolve thrombus	Activates plasminogen → plasmin to rapidly dissolve clot systemically	Local delivery of thrombolytic ± mechanical fragmentation directly at clot site
Indication	All confirmed PE (foundation of therapy)	Massive PE with hemodynamic instability	Submassive PE with clinical deterioration or contraindications to systemic lysis
Agents	UFH, LMWH (enoxaparin), DOACs (rivaroxaban, apixaban)	Alteplase (tPA), tenecteplase, streptokinase	Low-dose tPA via catheter ± ultrasound-assisted delivery (EKOS)
Major Bleeding Risk	1–3%	9–20% (including 1–3% intracranial hemorrhage)	~5–10% (reduced systemic exposure)
RV Recovery	Gradual over days to weeks	Rapid (within 24–48 hours)	Intermediate (24–72 hours)

Comparison of PE treatment strategies

Looking forward, several areas of active investigation are shaping the future of PE management. Pulmonary embolism response teams (PERTs) are multidisciplinary groups that convene rapidly to make time-sensitive treatment decisions for intermediate- and high-risk PE, analogous to STEMI teams in cardiology. Ongoing trials are evaluating reduced-dose systemic thrombolysis (e.g., half-dose alteplase) to preserve efficacy while reducing bleeding complications. Additionally, chronic thromboembolic pulmonary hypertension (CTEPH) is increasingly recognized as a long-term consequence of PE, occurring in 2–4% of survivors, and represents a bridge between acute PE pathophysiology and the chronic pulmonary hypertension domain. Pulmonary endarterectomy (PEA) and balloon pulmonary angioplasty (BPA) are established treatments for CTEPH, while the oral soluble guanylate cyclase stimulator riociguat offers pharmacological therapy for inoperable cases.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Explain why pulmonary embolism produces hypoxemia despite the fact that the affected alveoli are still being ventilated. In your answer, distinguish between the contribution of dead space ventilation and intrapulmonary shunting to the overall V/Q mismatch.

Show answer

In PE, the obstruction of pulmonary arterial flow to certain lung segments creates alveolar dead space—these alveoli are ventilated but not perfused (V/Q → ∞), so no gas exchange occurs and ventilation is wasted. However, blood must still traverse the pulmonary circulation, so it is redirected to the remaining patent vasculature. These unobstructed regions become relatively overperfused for their ventilation capacity (V/Q → 0), approximating an intrapulmonary shunt. Mixed venous blood passing through these overperfused units is incompletely oxygenated, and the resulting admixture lowers the overall arterial PaO₂. Additionally, neurohumoral mediators such as serotonin and thromboxane A₂ can cause bronchoconstriction in ventilated regions, further degrading V/Q matching. Thus, hypoxemia results from the combination of wasted ventilation (dead space) and shunt physiology in the remaining functional lung.

Question 2: BASIC CALCULATION

A patient breathing room air (FiO₂ = 0.21) at sea level has an ABG showing PaCO₂ = 32 mmHg and PaO₂ = 68 mmHg. Calculate the A-a gradient and interpret whether it is consistent with pulmonary embolism. (Use P_atm = 760 mmHg,

P_H

₂O = 47 mmHg, R = 0.8.)

Show answer

First, calculate the alveolar PO₂ using the alveolar gas equation: PAO₂ = FiO₂ × (760 − 47) − (PaCO₂ / R) = 0.21 × 713 − (32 / 0.8) = 149.7 − 40 = 109.7 mmHg. The A-a gradient = PAO₂ − PaO₂ = 109.7 − 68 = 41.7 mmHg. A normal A-a gradient for a young adult is approximately 5–15 mmHg, so this value of ~42 mmHg is markedly elevated. Combined with the respiratory alkalosis (low PaCO₂ indicating compensatory hyperventilation), this widened A-a gradient is highly consistent with a gas exchange defect such as pulmonary embolism. The pattern—hypoxemia with a widened A-a gradient and respiratory alkalosis—is the classic ABG signature of PE.

Question 3: INTERMEDIATE

A 55-year-old man with newly diagnosed lung cancer presents with dyspnea. His heart rate is 112 bpm, blood pressure is 118/76 mmHg, and SpO₂ is 88% on room air. CTPA shows bilateral PE with an RV/LV ratio of 1.4. Troponin T is 0.18 ng/mL (elevated). Calculate his sPESI score, classify the PE severity, and outline your initial management plan with pathophysiological justification for each intervention.

Show answer

The sPESI score is calculated as follows: Age >80 (no, 0), Cancer (yes, +1), Heart failure/chronic lung disease (no, 0), HR ≥110 (yes, +1), SBP <100 (no, 0), SpO₂ <90% (yes, +1). Total sPESI = 3, indicating non-low-risk. Although he is hemodynamically stable (SBP >90), the presence of RV dilation (RV/LV >1.0), elevated troponin, and high sPESI classify this as intermediate-high risk (submassive) PE per ESC guidelines. Initial management: (1) Start IV unfractionated heparin—bolus followed by continuous infusion—to prevent clot propagation and allow endogenous fibrinolysis; heparin is preferred over DOACs initially because of potential need for dose adjustment or emergent procedures. (2) Supplemental oxygen to correct hypoxemia, targeting SpO₂ >92%, thereby improving tissue oxygen delivery. (3) ICU admission for continuous hemodynamic monitoring because submassive PE patients carry a 3–15% mortality risk and may decompensate acutely. (4) Activate PERT consultation to evaluate candidacy for catheter-directed therapy if clinical deterioration occurs. (5) IVC filter consideration may arise given the active malignancy, though anticoagulation remains the primary therapy.

Question 4: APPLIED

A postoperative patient on your surgical service (day 3 after abdominal surgery) develops sudden dyspnea, tachycardia, and hypotension (BP 78/50 mmHg) unresponsive to 2 liters of IV crystalloid. Bedside echocardiogram shows severe RV dilation with interventricular septal bowing toward the left ventricle. CTPA is pending. Applying your knowledge of PE pathophysiology, explain: (a) Why is fluid resuscitation often harmful in massive PE? (b) What is the physiological rationale for initiating vasopressors versus inotropes? (c) Should empiric thrombolysis be considered before CTPA confirmation?

Show answer

(a) In massive PE, the right ventricle is already acutely dilated from the sudden rise in pulmonary vascular resistance. Aggressive fluid loading further distends the RV, exacerbating interventricular septal bowing into the LV cavity (ventricular interdependence), which impairs LV filling and paradoxically reduces cardiac output. Small fluid boluses (250–500 mL) may be trialed cautiously, but the classic teaching is that excessive volume resuscitation worsens hemodynamics in obstructive shock from PE. (b) Norepinephrine is the preferred vasopressor because it provides both α₁-mediated systemic vasoconstriction (maintaining coronary perfusion pressure, which the RV now desperately needs) and β₁-mediated inotropy to support RV contractility. Dobutamine, a pure inotrope, may additionally augment RV systolic function but can lower systemic vascular resistance through β₂ effects, potentially worsening hypotension; thus it is typically added as a second-line agent after vasopressor support is established. (c) Yes, in the setting of massive PE with hemodynamic collapse and echocardiographic evidence strongly suggestive of acute RV pressure overload, empiric systemic thrombolysis (e.g., alteplase 100 mg IV over 2 hours) should be strongly considered even before CTPA confirmation, as the mortality of untreated massive PE far exceeds the bleeding risk of thrombolysis. This decision exemplifies how pathophysiological reasoning—the rapidly progressing RV failure cycle—justifies action before definitive imaging in extremis.

Question 5: CRITICAL THINKING

A 30-year-old woman on oral contraceptives presents with acute dyspnea and hemoptysis. Her Wells score is 7.5 (PE likely). CTPA shows a small subsegmental PE in the right lower lobe with no evidence of RV strain. Troponin and BNP are normal. She is hemodynamically stable. Some recent literature suggests that isolated subsegmental PE may not always require anticoagulation. Construct an argument for and against anticoagulation in this case, integrating your understanding of PE pathophysiology, the natural history of venous thromboembolism, and the risks of therapy.

Show answer

Arguments FOR anticoagulation: (1) This patient has an identifiable ongoing risk factor (oral contraceptive-related hypercoagulability), meaning the prothrombotic environment persists and could drive recurrent or propagating thrombosis if left untreated. (2) The embolic event confirms the existence of a DVT source, even if a proximal DVT is not identified on duplex ultrasound; the thrombus may have fully embolized but the thrombotic milieu remains. (3) Although the current clot burden is small with no RV strain, untreated VTE carries a recurrence rate of approximately 20–25% over 5 years, and a subsequent embolism might involve a larger vascular territory. (4) The hemoptysis indicates pulmonary infarction with tissue damage, confirming clinical significance of the embolus. Arguments AGAINST anticoagulation: (1) Isolated subsegmental PE without proximal DVT has been shown in observational studies to carry a very low recurrence rate (~3% at 90 days) even without treatment. (2) Anticoagulation carries a 1–3% annual risk of major bleeding, which in a young patient represents a real iatrogenic hazard. (3) The clinical significance of subsegmental PE detected on modern high-resolution CTPA is debated; some represent false positives or clinically inconsequential findings that older scanners would not have detected. Synthesis: Given the patient's ongoing modifiable risk factor (OCP use), confirmed tissue infarction (hemoptysis), and high clinical probability (Wells 7.5), the balance of evidence favors a course of anticoagulation—typically 3 months with a DOAC—coupled with discontinuation of oral contraceptives. Serial duplex ultrasound surveillance would be an alternative only if anticoagulation is truly contraindicated. This case illustrates how pathophysiological context (hypercoagulable state) and clinical features (hemoptysis, high pretest probability) must modulate the interpretation of imaging findings.

SUMMARY

Pulmonary Embolism — Summary

Summary

Pulmonary embolism occurs when a thrombus, typically originating from deep venous thrombosis in the lower extremities, embolizes to the pulmonary arterial tree. Risk factors are encapsulated by Virchow's triad—venous stasis, endothelial injury, and hypercoagulability. The pathophysiology involves two parallel cascades: a hemodynamic pathway in which elevated pulmonary vascular resistance leads to right ventricular failure and decreased cardiac output, and a gas exchange pathway in which alveolar dead space and V/Q mismatch cause hypoxemia. Neurohumoral mediators (serotonin, thromboxane A₂) amplify both pathways beyond the degree of mechanical obstruction.

Diagnosis follows a risk-stratified algorithm: clinical probability scoring (Wells score), D-dimer for exclusion in low-probability patients, and CT pulmonary angiography as the definitive imaging study. Severity classification uses the sPESI score, RV function assessment, and cardiac biomarkers to stratify patients into low-risk, intermediate-risk (submassive), and high-risk (massive) categories. Treatment is risk-adapted: anticoagulation forms the foundation for all patients, systemic thrombolysis is indicated for massive PE, and catheter-directed therapy represents an intermediate option for submassive PE with clinical deterioration. Long-term, survivors face the risk of chronic thromboembolic pulmonary hypertension (CTEPH), bridging acute PE pathophysiology to the broader domain of pulmonary vascular disease.